Key result
Vein of Marshall ethanol infusion does not improve left atrial appendage occlusion rates at 60 days.
Why the study?
EI-VOM can cause prominent coumadin ridge edema and atrial infarction, but whether these lesions affect the efficacy and safety of LAAO had not been reported.
Does ethanol infusion in the vein of Marshall affect the feasibility and safety of left atrial appendage occlusion in patients undergoing radiofrequency catheter ablation?
Cohort (n=100)
No
Does ethanol infusion in the vein of Marshall affect the feasibility and safety of left atrial appendage occlusion in patients undergoing radiofrequency catheter ablation?
Ethanol infusion in the vein of Marshall during catheter ablation does not compromise the procedural feasibility, safety, or short-term efficacy of concomitant left atrial appendage occlusion.
Answers are grounded in this paper and cite their sources.
Ethanol infusion appears compatible with LAAO; leaves open its role in combined AF procedures pending randomized trials.
Background: Ethanol infusion in the vein of Marshall (EI-VOM) has the advantages of reducing the burden of atrial fibrillation (AF), decreasing AF recurrence, and facilitating left pulmonary vein isolation and mitral isthmus bidirectional conduction block. Moreover, it can lead to prominent edema of the coumadin ridge and atrial infarction. Whether these lesions will affect the efficacy and safety of left atrial appendage occlusion (LAAO) has not yet been reported. Objectives: To explore the clinical outcome of EI-VOM on LAAO during implantation and after 60 days of follow-up. Methods: A total of 100 consecutive patients who underwent radiofrequency catheter ablation combined with LAAO were enrolled in this study. Patients who also underwent EI-VOM at the same period of LAAO were assigned to group 1 (n = 26), and those who did not undergo EI-VOM were assigned to group 2 (n = 74). The feasibility outcomes included intra-procedural LAAO parameters and follow-up LAAO results involving device-related thrombus, a peri-device leak (PDL), and adequate occlusion (defined as a PDL ≤ 5 mm). Safety outcomes were defined as the composites of severe adverse events and cardiac function. Outpatient follow-up was performed 60 days post-procedure. Results: Intra-procedural LAAO parameters, including the rate of device reselection, rate of device redeployment, rate of intra-procedural PDLs, and total LAAO time, were comparable between groups. Furthermore, intra-procedural adequate occlusion was achieved in all patients. After a median of 68 days, 94 (94.0%) patients received their first radiographic examination. Device-related thrombus was not detected in the follow-up populations. The incidence of follow-up PDLs was similar between the two groups (28.0% vs. 33.3%, p = 0.803). The incidence of adequate occlusion was comparable between groups (96.0% vs. 98.6%, p = 0.463). In group 1, none of the patients experienced severe adverse events. Ethanol infusion significantly reduced the right atrial diameter. Conclusions: The present study showed that undergoing an EI-VOM procedure did not impact the operation or effectiveness of LAAO. Combining EI-VOM with LAAO was safe and effective.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2023) conducted a cohort in Atrial fibrillation (n=100). Ethanol infusion in the vein of Marshall (EI-VOM) vs. No EI-VOM (LAAO + RFCA only) was evaluated on Adequate left atrial appendage occlusion at follow-up (p=0.463). Ethanol infusion in the vein of Marshall did not significantly impact the rate of adequate left atrial appendage occlusion compared to the control group at 60-day follow-up (96.0% vs. 98.6%, p=0.463).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: